GLPwatch
FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.
JACC Adv · 2026
Last updated 2026-05-28| Journal | JACC Adv, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 41576595 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.